{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["66(6)"],"submitter":["Diamond TL"],"funding":["Merck"],"pubmed_abstract":["Islatravir (ISL) is a nucleoside reverse transcriptase translocation inhibitor (NRTTI) that inhibits human immunodeficiency virus (HIV) reverse transcription by blocking reverse transcriptase (RT) translocation on the primer:template. ISL is being developed for the treatment of HIV-1 infection. To expand our knowledge of viral variants that may confer reduced susceptibility to ISL, resistance selection studies were conducted with wild-type (WT) subtype A, B, and C viruses. RT mutations encoding M184I and M184V were the most frequently observed changes. Selection studies were also initiated with virus containing a single known resistance-associated mutation in RT (K65R, L74I, V90I, M184I, or M184V), and no additional mutations were observed. Antiviral activity assays were performed on varia"],"journal":["Antimicrobial agents and chemotherapy"],"pagination":["e0013322"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9211433"],"repository":["biostudies-literature"],"pubmed_title":["Islatravir Has a High Barrier to Resistance and Exhibits a Differentiated Resistance Profile from Approved Nucleoside Reverse Transcriptase Inhibitors (NRTIs)."],"pmcid":["PMC9211433"],"pubmed_authors":["Xu M","Lai MT","Diamond TL","Ngo W","Grobler JA","Rodriguez S","Goh SL","Asante-Appiah E"],"additional_accession":[]},"is_claimable":false,"name":"Islatravir Has a High Barrier to Resistance and Exhibits a Differentiated Resistance Profile from Approved Nucleoside Reverse Transcriptase Inhibitors (NRTIs).","description":"Islatravir (ISL) is a nucleoside reverse transcriptase translocation inhibitor (NRTTI) that inhibits human immunodeficiency virus (HIV) reverse transcription by blocking reverse transcriptase (RT) translocation on the primer:template. ISL is being developed for the treatment of HIV-1 infection. To expand our knowledge of viral variants that may confer reduced susceptibility to ISL, resistance selection studies were conducted with wild-type (WT) subtype A, B, and C viruses. RT mutations encoding M184I and M184V were the most frequently observed changes. Selection studies were also initiated with virus containing a single known resistance-associated mutation in RT (K65R, L74I, V90I, M184I, or M184V), and no additional mutations were observed. Antiviral activity assays were performed on varia","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jun","modification":"2026-06-15T05:45:20.349Z","creation":"2025-04-22T16:34:36.353Z"},"accession":"S-EPMC9211433","cross_references":{"pubmed":["35546110"],"doi":["10.1128/aac.00133-22"]}}